STAAR Surgical (NASDAQ:STAA) Shares Acquired by Jupiter Asset Management Ltd.

Jupiter Asset Management Ltd. increased its stake in STAAR Surgical (NASDAQ:STAA - Free Report) by 36.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 377,249 shares of the medical instruments supplier's stock after buying an additional 101,373 shares during the quarter. Jupiter Asset Management Ltd. owned about 0.77% of STAAR Surgical worth $9,163,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the company. HighTower Advisors LLC raised its holdings in shares of STAAR Surgical by 42.6% in the fourth quarter. HighTower Advisors LLC now owns 12,956 shares of the medical instruments supplier's stock worth $315,000 after buying an additional 3,871 shares during the period. Lane Generational LLC bought a new position in shares of STAAR Surgical in the fourth quarter worth about $1,441,000. Yunqi Capital Ltd increased its stake in STAAR Surgical by 48.9% in the 4th quarter. Yunqi Capital Ltd now owns 767,413 shares of the medical instruments supplier's stock worth $18,640,000 after buying an additional 252,113 shares during the period. Amundi lifted its holdings in STAAR Surgical by 174.7% during the 4th quarter. Amundi now owns 23,785 shares of the medical instruments supplier's stock valued at $550,000 after buying an additional 15,128 shares in the last quarter. Finally, Edgestream Partners L.P. bought a new stake in shares of STAAR Surgical during the fourth quarter valued at approximately $1,152,000. Institutional investors own 96.70% of the company's stock.

Insider Activity

In related news, major shareholder Broadwood Partners, L.P. bought 259,616 shares of the stock in a transaction dated Wednesday, February 12th. The shares were purchased at an average price of $14.96 per share, for a total transaction of $3,883,855.36. Following the completion of the purchase, the insider now directly owns 11,137,623 shares of the company's stock, valued at $166,618,840.08. This represents a 2.39 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have acquired 857,343 shares of company stock valued at $14,213,132 in the last ninety days. Insiders own 1.00% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

STAA has been the topic of several research reports. BTIG Research downgraded STAAR Surgical from a "buy" rating to a "neutral" rating in a report on Wednesday, February 12th. Needham & Company LLC restated a "hold" rating on shares of STAAR Surgical in a report on Thursday, February 27th. Jefferies Financial Group downgraded shares of STAAR Surgical from a "buy" rating to a "hold" rating in a research note on Wednesday, February 12th. Stephens restated an "equal weight" rating and set a $28.00 target price on shares of STAAR Surgical in a report on Wednesday, February 12th. Finally, Canaccord Genuity Group cut their price target on STAAR Surgical from $28.00 to $17.00 and set a "hold" rating on the stock in a report on Thursday, February 13th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $26.86.

STAAR Surgical Price Performance

STAAR Surgical stock traded up $0.56 during trading hours on Monday, hitting $17.61. 784,031 shares of the stock traded hands, compared to its average volume of 753,849. STAAR Surgical has a 1 year low of $13.50 and a 1 year high of $52.68. The firm's 50 day moving average price is $20.40 and its 200-day moving average price is $26.13. The stock has a market capitalization of $868.61 million, a price-to-earnings ratio of -42.95 and a beta of 0.66.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.